Aug 2026
CAR-T and GvHD: Have We Engineered GvHD Out of Allogeneic CAR‑T Therapy?
A focused Perspective asks whether GvHD directed engineering has made clinically significant product-associated GvHD rare and whether allogeneic CAR-T must reduce donor-to-host alloreactivity while managing the distinct host-versus-graft barrier.
Nabeel Ahmed, Jawaria Jabeen
· Transplantation and Cellular... · 0 citations